Invesco Ltd. raised its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,108,201 shares of the medical research company's stock after acquiring an additional 120,111 shares during the quarter. Invesco Ltd. owned 0.74% of Agilent Technologies worth $283,216,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Arete Wealth Advisors LLC acquired a new stake in shares of Agilent Technologies during the 3rd quarter valued at approximately $215,000. Orion Portfolio Solutions LLC increased its stake in Agilent Technologies by 9.0% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 8,513 shares of the medical research company's stock valued at $1,264,000 after purchasing an additional 704 shares in the last quarter. MML Investors Services LLC raised its holdings in Agilent Technologies by 3.2% during the third quarter. MML Investors Services LLC now owns 43,205 shares of the medical research company's stock worth $6,415,000 after purchasing an additional 1,337 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its position in Agilent Technologies by 4.7% during the third quarter. Nomura Asset Management Co. Ltd. now owns 85,436 shares of the medical research company's stock worth $12,686,000 after purchasing an additional 3,843 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Agilent Technologies by 0.4% in the third quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company's stock valued at $1,028,241,000 after purchasing an additional 30,610 shares during the last quarter.
Insider Transactions at Agilent Technologies
In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares of the company's stock, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,638 shares of company stock valued at $731,229.
Analyst Upgrades and Downgrades
A has been the topic of several recent research reports. Citigroup boosted their price objective on shares of Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research report on Thursday, December 19th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Tuesday, December 24th. Robert W. Baird cut their price objective on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Barclays reduced their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, TD Cowen boosted their price target on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $146.25.
Get Our Latest Stock Analysis on Agilent Technologies
Agilent Technologies Stock Up 0.4 %
NYSE:A traded up $0.44 during mid-day trading on Wednesday, hitting $103.56. The company had a trading volume of 401,548 shares, compared to its average volume of 2,066,778. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $155.35. The business has a fifty day simple moving average of $122.01 and a 200-day simple moving average of $133.33. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $29.52 billion, a price-to-earnings ratio of 23.81, a PEG ratio of 2.96 and a beta of 1.19.
Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Equities analysts forecast that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.
Agilent Technologies Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is currently 22.76%.
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
See Also
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
